A share price of ARS Pharmaceuticals Inc [SPRY] is currently trading at $10.66, down -2.47%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SPRY shares have gain 3.19% over the last week, with a monthly amount glided 7.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ARS Pharmaceuticals Inc [NASDAQ: SPRY] stock has seen the most recent analyst activity on September 04, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $40. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $30. On February 10, 2025, Oppenheimer initiated with a Outperform rating and assigned a price target of $40 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Raymond James upgraded its rating to a Strong Buy and raised its price target to $22 on August 13, 2024. Leerink Partners reiterated a Outperform rating for this stock on August 12, 2024, and upped its price target to $20. In a note dated July 25, 2024, Raymond James initiated an Outperform rating and provided a target price of $18 on this stock.
ARS Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $9.34 and $18.90. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $10.66 at the most recent close of the market. An investor can expect a potential return of 200.19% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
Trailing Twelve Months sales for ARS Pharmaceuticals Inc [NASDAQ:SPRY] were 112.34M which represents 3043.40% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.42%, and Net Profit Margin reading is -0.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.22 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ARS Pharmaceuticals Inc [NASDAQ:SPRY] is 6.17. In addition, the Quick Ratio stands at 5.98 and the Cash Ratio stands at 1.13. Considering the valuation of this stock, the price to sales ratio is 9.38, the price to book ratio is 5.47.
Transactions by insiders
Recent insider trading involved Lowenthal Richard E, PRESIDENT AND CEO, that happened on Aug 21 ’25 when 50000.0 shares were sold. Chief Financial Officer, Scott Kathleen D. completed a deal on Aug 21 ’25 to sell 12500.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Tanimoto Sarina sold 37656.0 shares on Aug 20 ’25.
